tham khảo

(Trở về mục nội dung gốc: )

1.         Owusu-Darko, S., K. Diouf, and N.M. Nour, Elimination of maternal and neonatal tetanus: a 21st-century challenge. Rev, 2012. 5(3-4): p. e151-7.

2.         Prevots, D.R., Neonatal tetanus. Bull World Health Organ, 1998. 76 Suppl 2: p. 135-6.

3.         Liu, L., et al., Global, regional, and national causes of child mortality: an updated systematic analysis for 2010 with time trends since 2000. Lancet, 2012. 379(9832): p. 2151-61.

4.         WHO, Maternal and neonatal tetanus (MNT) elimination. Available on http://www.who.int/immunization/diseases/MNTE_initiative/en/index.html, 2012.

5.         Ngọc, H.T., Báo cáo kết quả thực hiện công tác tiêm chủng mở rộng, khu vực phía Nam, năm 2012, in Hội nghị tổng kết dự án tiêm chủng mở rộng và chương trình phòng chống bệnh dại khu vực phía Nam, 2012. 2012, Viện Pasteur TPHCM.

6.         Demicheli, V., A. Barale, and A. Rivetti, Vaccines for women to prevent neonatal tetanus. Cochrane Database Syst Rev, 2013. 2013(31).

7.         Vaccines for pregnant women. National network for immunization Information, 2009.

8.         CDC, Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap) in pregnant women--Advisory Committee on Immunization Practices (ACIP), 2012. MMWR, 2013. 62(7): p. 131-5.

9.         Scott, L. and P. McCormack, Reduced-Antigen, Combined Diphtheria, Tetanus, and Acellular Pertussis Vaccine, Adsorbed (Boostrix®). BioDrugs, 2012. 27(1): p. 75-81.

10.       Booy, R., et al., A decennial booster dose of reduced antigen content diphtheria, tetanus, acellular pertussis vaccine (Boostrix) is immunogenic and well tolerated in adults. Vaccine, 2010. 29(1): p. 45-50.

11.       Halperin, S.A., et al., Tolerability and antibody response in adolescents and adults revaccinated with tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine adsorbed (Tdap) 4-5 years after a previous dose. Vaccine, 2011. 29(46): p. 8459-65.

12.       Halperin, S.A., et al., Immune responses in adults to revaccination with a tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine 10 years after a previous dose. Vaccine, 2012. 30(5): p. 974-82.

13.       Halperin, S.A., et al., How soon after a prior tetanus-diphtheria vaccination can one give adult formulation tetanus-diphtheria-acellular pertussis vaccine? Pediatr Infect Dis J., 2006. 25(3): p. 195-200.

14.       Talbot, E.A., et al., The safety of immunizing with tetanus-diphtheria-acellular pertussis vaccine (Tdap) less than 2 years following previous tetanus vaccination: Experience during a mass vaccination campaign of healthcare personnel during a respiratory illness outbreak. Vaccine, 2010. 28(50): p. 8001-7.

15.       Beytout, J., et al., Safety of Tdap-IPV given one month after Td-IPV booster in healthy young adults: a placebo-controlled trial. Hum Vaccin., 2009. 5(5): p. 315-21. Epub 2009 May 1.

16.       Edsall, G., et al., Excessive use of tetanus toxoid boosters. Jama., 1967. 202(1): p. 111-3.

17.       Levine, L., J. Ipsen, Jr., and J.A. McComb, Adult immunization. Preparation and evaluation of combined fluid tetanus and diphtheria toxoids for adult use. Am J Hyg., 1961. 73: p. 20-35.

18.       Newell, K.W., et al., The use of Toxoid for the prevention of Tetanus neonatorum preliminary report of a double-blind controlled field trial. Bull World Health Organ., 1964. 30: p. 439-44.

19.       Hardegree, M.C., et al., Immunization against neonatal tetanus in New Guinea. Bull World Health Organ., 1970. 43(3): p. 439-51.

20.       Rasmussen, S.A., et al., Vaccines and pregnancy: Past, present, and future. Semin Fetal Neonatal Med, 2013. 2013(16): p. 00123-6.

21.       Zheteyeva, Y.A., et al., Adverse event reports after tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccines in pregnant women. Am J Obstet Gynecol, 2012. 207(1): p. 14.

22.       Healy, C.M., M.A. Rench, and C.J. Baker, Importance of timing of maternal combined tetanus, diphtheria, and acellular pertussis (Tdap) immunization and protection of young infants. Clin Infect Dis, 2013. 56(4): p. 539-44.

23.       Kirkland, K.B., et al., Kinetics of pertussis immune responses to tetanus-diphtheria-acellular pertussis vaccine in health care personnel: implications for outbreak control. Clin Infect Dis., 2009. 49(4): p. 584-7. doi: 10.1086/603555.

24.       Halperin, B.A., et al., Kinetics of the antibody response to tetanus-diphtheria-acellular pertussis vaccine in women of childbearing age and postpartum women. Clin Infect Dis, 2011. 53(9): p. 885-92.

25.       WHO, Core information for the development of immunization policy 2002 update. Available on www.who.int/reproductivehealth/publications/maternal_perinatal_health/immunization_tetanus.pdf  2002.

26.       ACOG, Update on immunization and pregnancy: tetanus, diphtheria, and pertussis vaccination. Obstet Gynecol, 2013. 121(6): p. 1411-4.

27.       CDC, Update: Vaccine Side Effects, Adverse Reactions, Contraindications, and Precautions Recommendations of the Advisory Committee on Immunization Practices (ACIP). 1996.

Tải về tài liệu chính .....(xem tiếp)

Trở về mục nội dung gốc: